Targeting MCT1 suppresses humoral response and autoimmunity via the NAD(H) redox state
International Immunopharmacology · 2026-12 · 190 · 117553
DOI: 10.1016/j.intimp.2026.117553 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Shu-Li Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014,…. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Symporters, NAD, Myasthenia Gravis, Autoimmune, Experimental. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Postdoctoral Innovation Project of Shandong Province, National Natural Science Foundation of China, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Immunometabolism has garnered significant attention due to its essential roles in regulating B cell activation, proliferation and differentiation. Monocarboxylate transporters (MCTs), a family of solute carrier transporters responsible for lactate transport across biological membranes, have been shown to play a pivotal role in immune responses across various immune cell types. However, the expression and functional significance of MCTs in B cells remain poorly understood. In this study, we demonstrated that germinal center B cells and activated B cells exhibit elevated levels of MCT1 expression. Pharmacologically blocking MCT1 with AZD3965 inhibited both T-cell dependent and independent humoral response and ameliorated autoimmunity in the experimental autoimmune myasthenia gravis. Mechanically, MCT1 blockade led to the accumulation of intracellular lactate, which in turn suppressed NAD+ regeneration, thereby inhibiting B cell activation and survival. Taken together, these findings suggest that MCT1 might be a potential therapeutical target in antibody-mediate autoimmune disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China.
- Department of Pharmacy, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China.
- Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China; Shandong Institute of Neuroimmunology, Ji…
Förderung
- Postdoctoral Innovation Project of Shandong Province
- National Natural Science Foundation of China
- Taishan Scholar Foundation of Shandong Province
- Shandong Province Natural Science Foundation
- Shandong First Medical University
Zitieren
APA
Wei, S. L., Yang, Y., Wang, C. C., Li, X. M., Li, Y. W., Li, X. L., Zhou, Y., Du, T., Liu, R. T., Liu, Y., Yang, B., Duan, R. S., Zhang, P., & Yang, C. L. (2026). Targeting MCT1 suppresses humoral response and autoimmunity via the NAD(H) redox state. International Immunopharmacology, 190, 117553. https://doi.org/10.1016/j.intimp.2026.117553
Vancouver
Wei SL, Yang Y, Wang CC, Li XM, Li YW, Li XL, et al. Targeting MCT1 suppresses humoral response and autoimmunity via the NAD(H) redox state. International Immunopharmacology. 2026;190:117553. doi:10.1016/j.intimp.2026.117553
BibTeX
@article{Wei2026,
author = {Wei, Shu-Li and Yang, Ying and Wang, Cong-Cong and Li, Xue-Min and Li, Yuan-Wei and Li, Xiao-Li and Zhou, Yang and Du, Tong and Liu, Ru-Tao and Liu, Ying and Yang, Bing and Duan, Rui-Sheng and Zhang, Peng and Yang, Chun-Lin},
title = {Targeting MCT1 suppresses humoral response and autoimmunity via the NAD(H) redox state},
journal = {International Immunopharmacology},
year = {2026},
volume = {190},
pages = {117553},
doi = {10.1016/j.intimp.2026.117553}
}
EUVIMED